Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
What Glenmark files
- Updates77
- Others38
- Investor Meet32
- Important18
- Dividend/Bonus8
- PPTs7
Glenmark Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 11, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS® Launch in Brazil ".
India Ratings and Research (Ind-Ra) has upgraded Glenmark Pharmaceuticals Limited’s long-term bank loans to ‘IND AA+’ with a Stable Outlook, while affirming the short-term bank loans at ‘IND A1+’. Additionally, the agency has assigned ‘IND AA+/Stable/IND A1+’ ratings to new bank loan facilities worth 4,150 Cr. The upgrade reflects strengthened...
Glenmark's US unit launched Calcium Gluconate Injection USP, strengthening its injectables business. This product enters a US market with estimated annual sales of ~$69.9 million (~₹580 Cr), enhancing its hospital portfolio.
Glenmark Pharma received US approval for its Fluticasone Propionate Nasal Spray, a generic equivalent to Flonase®. This boosts their US respiratory portfolio, targeting a market with $295.2 million in annual sales.